The role of intrinsic pathway in apoptosis activation and progression in Peyronie&apos;s Disease. by Loreto, C. et al.
Research Article
The Role of Intrinsic Pathway in Apoptosis Activation and
Progression in Peyronie’s Disease
Carla Loreto,1 Giampiero La Rocca,2 Rita Anzalone,2
Rosario Caltabiano,3 Giuseppe Vespasiani,4 Sergio Castorina,1
David J. Ralph,5 Selim Cellek,6 Giuseppe Musumeci,1 Salvatore Giunta,1
Rados Djinovic,7 Dragoslav Basic,8 and Salvatore Sansalone4
1 Department of Bio-Medical Sciences, Anatomy and Histology Section, University of Catania, Via S. Sofia 87, 95123 Catania, Italy
2 Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, 90100 Palermo, Italy
3 Department G.F. Ingrassia Section of Anatomic Pathology University of Catania, 95123 Catania, Italy
4Department of Urology, School of Medicine Tor Vergata University of Rome, 00133 Rome, Italy
5 University College London Hospital, London WC1E 6BT, UK
6Cranfield Health Cranfield University, MK43 0AL, UK
7 Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, 11000 Belgrade, Serbia
8 Clinic of Urology, Clinical Center Nis, 18000 Nis, Serbia
Correspondence should be addressed to Carla Loreto; carla.loreto@unict.it
Received 26 February 2014; Accepted 31 May 2014; Published 13 August 2014
Academic Editor: Ralf Herwig
Copyright © 2014 Carla Loreto et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Peyronie’s disease (PD) is characterized with formation of fibrous plaques which result in penile deformity, pain, and erectile
dysfunction. The aim of this study was to investigate the activation of the intrinsic apoptotic pathway in plaques from PD patients.
Tunica albuginea from either PD or control patients was assessed for the expression of bax, bcl-2 and caspases 9 and 3 using
immunohistochemistry and bymeasurement of apoptotic cells using TUNEL assay. Bax overexpressionwas observed inmetaplastic
bone tissue, in fibroblasts, and in myofibroblast of plaques from PD patients. Little or no bcl-2 immunostaining was detected
in samples from either patients or controls. Caspase 3 immunostaining was very strong in fibrous tissue, in metaplasic bone
osteocytes, and in primary ossification center osteoblasts. Moderate caspase 9 immunostaining was seen in fibrous cells plaques
and in osteocytes and osteoblasts of primary ossification centers from PD patients. Control samples were negative for caspase 9
immunostaining. In PD patients the TUNEL immunoassay showed intense immunostaining of fibroblasts and myofibroblasts, the
absence of apoptotic cells in metaplasic bone tissue and on the border between fibrous and metaplastic bone tissue. Apoptosis
occurs in stabilized PD plaques and is partly induced by the intrinsic pathway.
1. Introduction
Peyronie’s disease (PD) is a connective tissue disorder where
formation of fibrous plaques in tunica albuginea (TA) and
erectile tissue can result in penile deformity, pain, and erectile
dysfunction [1–4]. Although PD is considered a localized
disorder, a recent biomolecular study seems to suggest the
involvement of the entire TA [5]. Fibrosis, its major patho-
logical manifestation, arises from fibroblast proliferation and
accumulation of extracellular matrix; PD progresses with
formation of plaques or even ectopic calcification having
the appearance of scar tissue, which prevents TA expansion
during erections [6, 7]. An external stress, sustained most
likely in the erect state (typically during sexual activity),
has been suggested to initiate plaque development [8]; the
resulting TA injury or tearing then is suggested to heal
abnormally [9].
The mechanisms underpinning PD are unclear [9–11],
and relatively little is known about the disease itself. As a
result effective medical treatments that can alter its course
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or progression are not yet available [7, 12]. To date cor-
rective surgery is the sole effective treatment. A greater
understanding of PD pathophysiology at the molecular level
has the potential to help develop novel medical therapeutic
approaches.
Apoptosis, or programmed cell death, is a fundamental
mechanism with a key role throughout development [13].
In the fully formed organism it mediates the maintenance
of tissue homeostasis involved in normal tissue turnover,
whereas its dysregulation plays a role in multiple disease
processes [14]. Apoptosis can take place either through the
extrinsic (death receptor-mediated) or the intrinsic (mito-
chondrial) pathway (Figure 1). The former pathway involves
activation of death signaling ligands like tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) through its
death receptors DR4 and DR5 and has a role in immune and
homeostasis processes [13, 15]; these events in turn activate
the initiator caspase 8, which cleaves and activates the exe-
cutioner caspase 3. Executioner caspases induce biochemical
andmorphological changes such as chromatin condensation,
nuclear fragmentation, and cytoskeletal degradation; once
they have been activated the apoptosis process becomes
irreversible.
The intrinsic mitochondrial pathway is activated by a
range of exogenous and endogenous stimuli including DNA
damage, ischemia, and oxidative stress (Figure 1).Moreover it
plays an important function in development and in elimina-
tion of damaged cells [13].The intrinsic pathway is influenced
by members of the bcl family bound to the mitochondrial
membrane, including bax and bcl-2, which act as pro- or
antiapoptotic regulatory proteins, respectively [16]. In the
intrinsic pathway the functional consequence of proapop-
totic signaling is mitochondrial membrane perturbation and
release of cytochrome C in the cytoplasm, where it forms a
complex or apoptosome with apoptotic protease activating
factor 1 (APAF1) and the inactive form of caspase 9. This
complex hydrolyzes adenosine triphosphate to cleave and
activate caspase 9. The initiator caspase 9 then cleaves and
activates the executioner caspases 3, 6, and 7, resulting in cell
apoptosis [14, 17].The antiapoptotic proteins bcl-2 and bcl-XL
inhibit cytochrome C release [18].
We have previously described apoptotic cell death in TA
plaques from patients with PD and demonstrated its activa-
tion via the extrinsic pathway by assessing an overexpression
of tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) and its death receptor, DR5, in fibroblast and
myofibroblast cells [19]. Following up on this previous work,
we have decided to investigate the possible activation of the
intrinsic pathway through the study of bax, bcl-2, caspase 9,
the activation of caspase 3 (the point of no return leading
irreversibly to cell death), and the TUNEL assay, which
documents DNA fragmentation and hence the achievement
of the apoptosis process.
2. Materials and Methods
2.1. Patients and Tissues. Wedge-shaped biopsy specimens
(approximately 3 × 5mm) were collected from 15 patients
(mean age 53 ± 10 years; range 31–67) at the level of the
corporotomy during corrective surgery for PD. All patients,
who had had stable PD for at least 6 months, underwent
albugineal grafting using the geometrical principle as origi-
nally described by Egydio and Sansalone [20]. The TA was
incised and grafted at the level of the maximum penile
curvature, where plaque formation was most prominent [21].
The study protocol was approved by the ethics committee
of the Clinic of Urology, Clinical Center Nis, Nis, Serbia. The
informed consent of each patient was obtained before tissue
collection.
During preoperative examination all patients reported
having spontaneous erections but being prevented from
regular sexual intercourse by a penile curvature of above 45∘.
Degree of penile curvature and rigidity were evaluated with
Doppler ultrasonography after intracavernous injection of
10–20 𝜇g alprostadil.
Control samples were specimens from 4 patients (mean
age 23 ± 3 years; range 21–27) with congenital penile curva-
ture who underwent Nesbit’s corrective procedure [22].Their
clinical history was negative for generalized penile disease;
none hadmacroscopic signs of degenerative or inflammatory
disorders. Histological examination using Mayer’s hema-
toxylin (Histolab Products AB, Sweden) and eosin (Histolab
Products AB, Sweden) showed no detectable pathological
abnormalities (not shown).
2.2. Immunohistochemistry. For the immunohistochemical
studies, PD plaques were fixed overnight in 10% neutral
buffered formalin (Bio-Optica, Italy). After fixation and
overnight washing in water they were dehydrated in graded
ethanol and paraffin-embedded. They were then cut into
5 𝜇m thick sections, using a microtome (Hn40, Reichert-
Jung, USA) and placed on silanized glass slides. After rehy-
dration endogenous peroxidase activity was quenched by
treatment with 3% H
2
O
2
for 10min as previously described
[23]. Nonspecific antibody binding was blocked by treatment
with normal horse/goat serum diluted 1 : 20 in phosphate
buffered saline (PBS), 0.1% bovine serum albumin (BSA,
Roche Applied Science, Germany). Sections were treated
(5min × 3 times) in capped polypropylene slide-holders with
citrate buffer (pH 6) using a microwave oven (750W) to
unmask antigen sites.
The following primary antibodies were used: rabbit
polyclonal antihuman bax (1 : 100, Dako, Denmark), mouse
monoclonal antibody antihuman bcl-2 (Dako, Denmark),
mouse monoclonal antihuman caspase 9 (1 : 100, Santa Cruz
Biotechnology, USA), and rabbit monoclonal antihuman
caspase 3 (1 : 50, Abcam, UK). The primary antibodies were
applied directly onto sections and slides were incubated
overnight (4∘C) in a humid chamber. The sections were then
washed in PBS and treated with a biotinylated antibody
and detected using peroxidase-labeled streptavidin, both
incubated for 10min at room temperature (LSAB+System-
HRP, Dako Italy).
The immunoreaction was assessed using a Zeiss Axioplan
light microscope (Oberkochen, Germany) after incubating
sections in 0.1% 3,3󸀠-diaminobenzidine and 0.02% hydrogen
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Figure 1: Apoptosis works through two main, alternative pathways: death receptor-mediated (or extrinsic) and mitochondria-dependent
(or intrinsic). The former pathway is initiated by ligation of specific death receptors by their ligands. The main death receptors—Fas and
tumour necrosis factor- (TNF-) related apoptosis inducing ligand (TRAIL) receptors DR4 and DR5—induce cell death following ligation
with Fas ligand (FasL) or TRAIL, respectively, followed by recruitment of procaspase 8. This process gives rise to caspase 8 activation. The
latter induces apoptosis by directly activating caspase 3 or by cleaving bid (BH3 interacting domain death agonist), resulting in mitochondrial
dysfunction and subsequent release of cytochrome C and activation of caspases 9 and 3. Caspase 3 promotes the typical apoptosis features,
including DNA fragmentation and cell death in several tissues.Themitochondrial pathway is partly influenced by bcl family members bound
to themitochondrial membrane, including bax and bcl-2, which are, respectively, pro- or antiapoptotic regulatory proteins.The antiapoptotic
proteins bcl-2 and bcl-XL inhibit cytochrome c release, whereas bcl-2—associated X protein(bax), bcl-2 homologous antagonist/killer (bak),
and bid, all proapoptotic proteins, promote its release from mitochondria. Cytochrome C and deoxyadenosine triphosphate (dATP) bind to
apoptotic protease activating factor (APAF-1) to form a multimeric complex that recruits and activates procaspase 9, an apoptosis-mediating
executioner protease that in turn activates caspase 3, resulting in cell apoptosis.
peroxide solution (DAB substrate kit, Vector Laboratories,
Burlingame, CA, USA) for 4min. Sections were lightly
counterstained with Mayer’s hematoxylin and then mounted
on GVA mount (Zymed Laboratories, San Francisco, CA,
USA).
2.3. Evaluation of Immunohistochemical Staining. Staining
for bax, bcl-2, caspase 9, and caspase 3 was classified as
negative/positive. Immunohistochemical staining was brown
chromogen detected on the edge of the hematoxylin-stained
cell nucleus or distributed in the cytoplasm or themembrane.
Intensity of staining (IS) was graded in a semiquantitative
manner using a 5-point scale: 0 = no detectable staining, 1 =
weak staining, 2 =moderate staining, 3 = strong staining, and
4 = very strong staining. The proportion of immunopositive
cells (extent score = ES) was evaluated at 20x magnification
blindly by two anatomists and a histologist. ES was scored as
a proportion of the final number of 100 cells into five classes:
<5% (0), 5–30% (+), 31–50% (++), 51–75% (+++), and >75%
(++++). Counting was performed at 20x magnification.
Positive and negative controls were run to test the specific
reaction of the primary antibodies used. Positive controls
were basal cell carcinoma specimens. For the negative con-
trols, randomly selected sections from PD patients were
treated with normal rabbit serum instead of the specific
antibodies.
2.4. In Situ Detection and Measurement of Apoptotic Cells
(TUNEL). In situ detection of apoptosis at the single cell level
was performed by terminal deoxynucleotidyl transferase-
(TdT-) mediated dUTP-biotin nick end labeling, TUNEL (In
Situ Cell Death Detection Kit, POD, Roche) as previously
described [24]. The method involves adding deoxyuridine
triphosphate (dUTP) labeled with fluorescein to the ends
of the DNA fragments by the catalytic action of TdT. End-
labeling experiments were performed in triplicate to enable
standardization of the results for the different tissue sam-
ples. Paraffin-embedded sections of 5 𝜇m thicknesses were
dewaxed. Slides were rinsed twice in 0.01M PBS (pH 7.4),
transferred to 0.07M citrate buffer (pH 6.0; Bio-Optica),
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and treated in a microwave oven at 750W for 1min for
permeabilization. Sections were then immersed in Tris-
HCl 0.1M (Roche), pH 7.5, containing 3% BSA and 20%
normal bovine serum (Sigma-Aldrich, St. Louis, MO, USA)
for 30min at 20∘C, rinsed twice in PBS, and immersed in
TdT buffer (Roche). Sections were then covered with TdT
and fluorescein-labeled dUTP in TdT buffer and incubated
in a dark humid chamber at 37∘C for 60min. They were
incubated with an antibody specific for fluorescein conju-
gated to peroxidase with 30min incubation at 37∘C. Staining
was visualized with DAB, which stains nuclei with DNA
fragmentation brown. Sections were counterstained with
Mayer’s hematoxylin. In negative controls TdT was omitted
from the reaction. Ten fields from randomly selected slides
were observed under a light microscope. Each field was
photographed with a digital camera (Canon, Japan) at 20x
and 40x magnification. On each photomicrograph the same
three observers, blinded to sample identity, counted the cells
exhibiting a positive TUNEL reaction. The proportion of
positive cells was calculated for each photomicrograph and
a mean value was obtained for each sample.
2.5. Computerized Image Analysis. To quantify immunohis-
tochemical staining, 10 sections/sample were analyzed in
stepwise fashion as a series of consecutive fields with a 40x
magnification; the stained area was expressed as pixels/field.
Randomly selected fields from each section were analyzed
and the percent area staining for bax, bcl-2, caspase 9, and
caspase 3 was calculated using AxioVision rel. 4.8.2 image
analysis software and an AxioVision 4 Module AutoMeasure
(Zeiss, Go¨ttingen,Germany) to quantify the level of immuno-
labeling in each field. Values from all consecutive images of
each biopsy were averaged. Digital pictures were taken using
an Axiocam camera (Zeiss, Go¨ttingen).
2.6. Statistical Analysis. Statistical analysis was performed
using SPSS software (rel. 16.0, Chicago, IL, USA). Com-
parisons between mean values were tested with Student’s
unpaired 𝑡-test. 𝑃 values less than 0.05 were considered sig-
nificant. Cohen’s kappa coefficient was used tomeasure inter-
observer agreement and averaged over the three observers.
Overall agreement was graded as follows: 0–0.2 (slight), 0.21–
0.40 (fair), 0.41–0.60 (moderate), 0.61–0.80 (substantial), and
0.81–1.0 (almost perfect).
3. Results
3.1. General Observations. On hematoxylin and eosin-
stained specimens the collagen fiber arrangement was mostly
disrupted. Fibers were affected to different degrees in all
PD patients, the damage involving fragmentation, tears, and
splitting. Elastic fibers were often fragmented; clumps of
collagen bundles and surrounding elastic fibers were also
noted. In contrast, control TA samples exhibited preserved
collagen bundles displaying longitudinal fiber orientation in
the outer layer and circular fibers in the inner layer (not
shown).
3.2. Bax Expression. PD plaques showed areas of osseous
metaplasia with heterotopic ossification (Figure 2(a), aster-
isk) and several osteocytes were detected in bone lacunae
(Figure 2(a), double arrowhead).
Immunohistochemical examination of sections from PD
plaques showed bax overexpression (IS: 4; ES: ++++) in
some osteocytes in metaplastic bone (Figure 2(b), arrow)
and in osteoblasts found in the primary ossification centers
(Figure 2(a), arrow). In particular bax overexpression was
detected in osteoblasts and fibroblasts on the border of the
metaplastic bone tissue (Figure 2(b), double arrowhead) and
in vessels (Figure 2(b), asterisk). Very strong bax positivity
was also demonstrated in PD plaques in the fibroblast cyto-
plasm and in the myofibroblast membrane and cytoplasm
(Figure 2(c)) (IS: 4; ES: ++++), whereas very few immunos-
tained cells were detected in control samples (Figure 2(d))
(IS: 3; ES: +). The percentage of bax immunopositive cells
in PD plaque and control tissue is shown in Figure 7(a).
Interobserver agreement was 0.94.
3.3. Bcl-2 Expression. Little or no bcl-2 immunostaining
was detected in samples from PD patients (IS: 1; ES: 0) or
from controls (IS: 2; ES: +) (Figures 3(a) and 3(b), resp.).
The percentage of bcl-2 immunopositive cells in PD plaque
and control tissue is shown in Figure 7(b). Interobserver
agreement was 0.95.
3.4. Caspase 3 Expression. Caspase 3 immunostaining was
very strong (IS: 4; ES: ++++) in fibroblasts lying on the border
between fibrous and metaplastic bone tissue; it was also
very strong in fibrous tissue (Figure 4(a), arrowheads) and in
metaplastic bone osteocytes (Figure 4(a), arrow). Haversian
canals (Figure 4(b), arrows) exhibiting primary ossification
centers (Figure 4(b), arrowhead) were observed in metaplas-
tic bone wherein a strong caspase 3 immunostaining was
found in osteoblasts. Little or no caspase 3 immunostaining
was seen in control samples (IS: 3; ES: 0) (Figure 3(c)). The
percentage of caspase 3 immunopositive cells in PD plaque
and control tissue is shown in Figure 7(c). Interobserver
agreement was 0.90.
3.5. Caspase 9 Expression. Moderate immunostaining
for caspase 9 was seen in fibrous cells from PD plaques
(Figure 5(a), arrows) and in osteocytes (arrow) and
osteoblasts of primary ossification centers (arrowhead)
(Figure 5(b)) (IS: 2; ES: +++). Control samples were negative
for caspase 9 immunostaining (Figure 5(c)) (IS: 0; ES: 0).
The percentage of bax immunopositive cells in PD plaque
and control tissue is shown in Figure 7(d). Interobserver
agreement was 0.89.
3.6. TUNEL Staining. The TUNEL immunoassay showed
intense staining of fibroblasts and myofibroblasts from PD
plaques (Figure 6(a)) and no stained cells in the metaplastic
bone tissue or on the border between fibrous and metaplastic
bone tissue (Figure 6(b)). Very few apoptotic cells were
detected in control specimens (Figure 6(c)). Quantitative
analysis of TUNEL-positive cell staining in PD samples is
reported in Figure 8.
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Figure 2: Bax immunostaining in plaque from a patient with Peyronie’s disease (a, b, c) and in control tissue (d); magnification is 20x for
all. Scale bar = 100𝜇m. Asterisk at (a): areas of osseous metaplasia with heterotopic ossification; double arrowhead: an osteocyte in bone
lacunae; arrow: bax overexpression in an osteoblast of a primary ossification center. Arrow at (b): bax overexpression in an osteocyte in
metaplastic bone; double arrowhead: bax overexpression in osteoblasts and fibroblasts on the border of the metaplastic bone tissue; asterisk:
bax overexpression in a blood vessel.
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Figure 3: Bcl-2 immunostaining in plaque from a patient with Peyronie’s disease (a) and in control tissue (b); magnification is 20x for all.
Scale bar = 100𝜇m.
4. Discussion
Even though PD has been described in the 18th century,
its pathogenic mechanism and molecular basis are poorly
understood and its therapeutic approach is still empirical
[25].
A previous study by our group documented the
involvement of the extrinsic pathway in the activation of
programmed cell death in PD. The present study examines
the possible activation of the intrinsic apoptotic pathway
through the immunohistochemical demonstration of
staining for a number of key molecules: bcl-2, bax, anti-
and proapoptotic oncoproteins, respectively, involved in
apoptosis regulation, modulating cell survival or death [26–
30], caspase 9, which is associated with the intrinsic pathway,
and the executioner caspase 3 (Figure 1). The study also
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Figure 4: Caspase 3 immunostaining in plaque from a patient with Peyronie’s disease ((a) and (b)) and in control tissue (c); magnification is
20x for all. Scale bar = 100𝜇m. (a) Arrowheads: caspase 3 immunostaining in fibrous tissue; arrow: caspase 3 immunostaining in ametaplastic
bone osteocyte. (b) Arrows: haversian canals; arrowhead: a primary ossification center.
seeks to demonstrate the completion of the apoptotic process
using the TUNEL assay. Bax upregulation and negative
bcl-2 immunostaining, associated with moderate caspase 9
activation, suggest that the apoptotic process documented
in PD patients is at least partly regulated by the intrinsic
pathway.
TA tissue from PD patients also exhibited upregulation of
caspase 3, the executioner caspase of the apoptotic cascade.
The apoptotic cascade has been subdivided into three sets of
stages. Initiation stages include induction of the cascade, for
instance, by ligand-receptor interactions or a cellular stress
leading to the first proteolytic event. Execution stages begin
with the activation of executioner caspases such as caspase 3:
this is called the “point of no return” since, once activated,
these proteases degrade a variety of proteins (including those
involved in DNA maintenance and repair such as PARP),
resulting in irreversible cell damage. These complex events
lead to apoptotic death, with collapse of the nucleus and of
the cell itself and DNA fragmentation [31].
The caspase 3 immunopositivity found in the plaques
from the PD patients, both in fibrous and in metaplastic
bone tissue, seems to be in contrast with the TUNEL test
results, which suggest that apoptotic cells are found in fibrous
tissue but are absent at the level of the osseous metaplasia.
However, the discrepancy can be accounted for by the fact
that the anticaspase 3 antibody used in these experiments
recognizes both the cleaved and the noncleaved form of the
protein. This suggests that whereas the apoptotic process
takes place in fibrous tissue as a defense mechanism, at the
level of the osseous metaplasia, where a degenerative process
is already under way, the apoptosis mechanism is already
activated but stops and does not continue with caspase 3
activation (cleavage). Apoptosis can therefore be regarded
as an injury-limiting mode of cell disposal [32]. Indeed
osseous metaplasia can be considered as a tissue adaptation
event responding to amicroenvironmental change, leading to
replacement of sensitive cells with less sensitive ones. Areas
of fibrous tissue subject to chronic trauma and a hypoxic
microenvironment may therefore give rise to formation
of bone tissue presumably from stem cells that undergo
osteogenic differentiation [33]. TA disruption in PD usually
involves a variety of steps that include a local increase in
microvascular permeability, persistent accumulation of fibrin
and collagen, perivascular inflammation, elastic fiber disrup-
tion and loss, disruption of collagen bundle organization,
increased synthesis of transforming growth factor 𝛽1 (TGF-
𝛽1), and ultimately calcification followed by ossification [34–
39]. Increased expression of TGF-𝛽1, plasminogen activator
inhibitor 1, reactive oxygen species (ROS), and other profi-
brotic factors as well as of inducible nitric oxide synthase
(iNOS) leads to fibroblast/myofibroblast proliferation and
collagen buildup [40, 41] as a defense mechanism against
oxidative stress. ROS, iNOS, and TGF-𝛽1 are capable of
inducing fibroblast and myofibroblast apoptosis [33, 42–
46]. In normal repair and healing a protective mechanism
clears myofibroblasts through apoptosis; however, failure of
BioMed Research International 7
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Figure 5: Caspase 9 immunostaining in plaque from a patient with Peyronie’s disease (a and b) and in control tissue (c); magnification is 20x
for all. Scale bar = 100 𝜇m. (a) Arrows: caspase 9 immunostaining in fibrous cells from PD plaques (Figure 5(a), arrows) and in osteocytes
(arrow). (b) Arrowheads: caspase 9 immunostaining in osteoblasts of a primary ossification centers.
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Figure 6: TUNEL staining in plaque from a patient with Peyronie’s disease ((a) and (b)) and in control tissue (c); magnification is 20x for all.
Scale bar = 100𝜇m.
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Figure 7: Quantitative analysis of bax (a), bcl-2 (b), caspase 3 (c), and caspase 9 (d) immunostaining in PD samples. In both panels, asterisks
indicate significant differences versus the control group (𝑃 < 0.05).
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Figure 8: Quantitative analysis of TUNEL-positive cell staining
in PD samples. Different cell positivity can be seen in areas with
osseous metaplasia and in fibrous tissue areas. Asterisks indicate
significant differences versus the control group (𝑃 < 0.01).
the mechanism entails their persistence inducing fibrosis,
collagen buildup, and tissue contraction [7]. Activation of
the apoptosis mechanism through the extrinsic pathway,
demonstrated in our previous paper, and via the mitochon-
drial pathway in the present one may be regarded as the
reason for plaque stabilization and the halting of fibrosis
progression. However, after activation the apoptosis process
could be blocked by endogenous apoptosis inhibitors, as
likely occurs in the osseous metaplasia area. Further in vivo
and in vitro research are therefore needed to gain insights into
this delicate process.
A study by Lucattelli et al. [47] demonstrated in a new
mouse model of PD that mice aged 12 months develop
osseous metaplasia, probably as a consequence of upregu-
lation of hypoxia-inducible factor-1 (HIF-1): this seems to
determine an increased expression of HIF-1 target genes
such as TGF-𝛽 and iNOS which, as noted above, are partly
responsible for apoptosis induction. This is probably why
therewere no apoptotic cells in the osseousmetaplasia region.
A further consideration emerging from the analysis of
our data is that the moderate expression of caspase 9 and
overexpression of caspase 3 indicate aweak role for the intrin-
sic pathway in programmed cell death, a role that is played
principally by the extrinsic pathway as demonstrated by our
previous findings. This is reasonable, since this pathway is
basically activated by death receptor binding with ligands
such as TRAIL, whereas the intrinsic pathway is activated by
exogenous stimuli such as inflammation-induced oxidative
stress (ROS) [40].
Recent studies have shown that phosphoinositide 3-
kinase (PI3K)/Akt signaling regulates fibrotic responses
including collagen synthesis and cell proliferation [48]. Jung
and colleagues synthesized HS-173, a novel PI3K inhibitor,
and found that it inhibited fibroblast growth in a dose-
dependent manner and induced apoptosis [48]. Although
these findings appear to contrast with ours, the discrepancy
may be ascribed to the fact that they were obtained in vivo or
that our samples contained stabilized plaque, likely through
apoptosis activation and achievement. Indeed it is well known
BioMed Research International 9
that when cells lack proliferation factors due, for instance, to
tissue overgrowth, they stop proliferating and often die by
apoptosis [14].
Previous studies have advanced the hypothesis of an
abnormal wound healing process in PD, possibly through a
failure of fibroblast apoptosis [49]. Alternatively the signif-
icant increase in the number of apoptotic cells detected in
PD plaques could be ascribed to an efficient mechanism of
programmed cell death leading to plaque stabilization; it may
therefore be hypothesized that although the apoptosis process
could be impaired during disease evolution, it might however
result in plaque stabilization. It would therefore be interesting
to study nonstabilized plaque to gain further insights into the
activation and progression of the apoptosis process.
In this study we tested the involvement of the intrinsic
apoptosis pathway and of executioner caspases in PD and
completed the experimental work with the TUNEL assay.
Novel therapeutic strategies, for instance, based on TRAIL
agonists, could help PD patients through enhancement of
myofibroblast death in the attempt to induce plaque stabiliza-
tion and prevent disease progression.
5. Conclusion
Apoptotic cell death occurs in stabilized PD plaques and is
partly induced by the intrinsic mitochondrial pathway. The
present findings can have clinical implications and may help
devise improved treatment strategies. A therapeutic approach
aimed at enhancing apoptosis-inducing molecules would
at least help delay the progression of PD. Identification of
target molecules for gene construct or biological or chemical
reagent delivery to target sites could contribute to inducing
PD plaque stabilization.
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